Dieter Volc

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

Dieter Volc, Werner Poewe, Alexandra Kutzelnigg et al. · The Lancet Neurology · 2020 · 132 citations

Neurodegenerative Diseases, Autoimmune Disease, Immunology +4

Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial

Jacques Montplaisir, Jeff Karrasch, J. Haan et al. · Movement Disorders · 2006 · 98 citations

Nicotinamide adenine dinucleotide (NADH) — a new therapeutic approach to Parkinson's disease

J. G. D. Birkmayer, C. Vrecko, Dieter Volc et al. · Acta Neurologica Scandinavica · 1993 · 93 citations

Non-pharmacological Intervention, Neurodegenerative Diseases, Biochemistry +15

A Phase 1 Randomized Trial of Specific Active <scp>α‐Synuclein</scp> Immunotherapies <scp>PD01A</scp> and <scp>PD03A</scp> in Multiple System Atrophy

Wassilios G. Meissner, Anne Pavy‐Le Traon, Alexandra Foubert‐Samier et al. · Movement Disorders · 2020 · 78 citations · Full text

624 BENEFITS OF AN ADD‐ON TREATMENT WITH THE SYNTHETIC CANNABINOMIMETIC NABILONE ON PATIENTS WITH CHRONIC PAIN‐A RANDOMIZED CONTROLLED TRIAL

Martin Pinsger, Wolfgang Schimetta, Dieter Volc et al. · European Journal of Pain · 2006 · 43 citations

Cannabis Use, Pain Therapy, Pain Disorders +11